-
Mahan CE, Spyropoulos AC. ASHP therapeutic position statement on the role of pharmacotherapy in preventing venous thromboembolism in hospitalized patients. Am J Health Syst Pharm. 2012 Dec 15; 69(24):2174-90.
-
Spyropoulos AC, Goldenberg NA, Kessler CM, Kittelson J, Schulman S, Turpie AG, Cutler NR, Hiatt WR, Halperin JL. Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm? J Thromb Haemost. 2012 Dec; 10(12):2621-4.
-
Spyropoulos AC, McGinn T, Khorana A. The use of weighted and scored risk assessment models for venous thromboembolism. Thromb Haemost. 2012 Nov 29; 108(6):1072-6.
-
Spyropoulos AC, Anderson FA. The "risk" of risk assessment models for venous thromboembolism in medical patients. Am J Med. 2012 Nov; 125(11):e23-4.
-
Nieuwlaat R, Hubers LM, Spyropoulos AC, Eikelboom JW, Connolly BJ, Van Spall HG, Schulze KM, Cuddy SM, Stehouwer AC, Schulman S, Connolly SJ. Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. Thromb Haemost. 2012 Nov 29; 108(6):1228-35.
-
Rochwerg B, Xenodemetropoulos T, Crowther M, Spyropoulos A. Dabigatran-induced acute hepatitis. Clin Appl Thromb Hemost. 2012 Sep; 18(5):549-50.
-
Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012 Oct 11; 120(15):2954-62.
-
Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin k antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012 Sep 25; 126(13):1630-9.
-
Khorana AA, Spyropoulos AC, Zwicker J, Lyman GH, Francis CW. Preventing VTE in Outpatients With Cancer. Chest. 2012 Jul 1; 142(1):265-6.
-
Moruf A, Spyropoulos AC, Schardt TQ, Gibson E, Manco-Johnson MJ, Wang M, Goldenberg NA. Peri-procedural bridging with low molecular weight heparin in patients receiving warfarin for venous thromboembolism: A pediatric experience. Thromb Res. 2012 Oct; 130(4):612-5.
-
Mahan CE, Borrego ME, Woersching AL, Federici R, Downey R, Tiongson J, Bieniarz MC, Cavanaugh BJ, Spyropoulos AC. Venous thromboembolism: Annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. Thromb Haemost. 2012 Jul 25; 108(2):291-302.
-
Spyropoulos AC. Pro: "Bridging anticoagulation is needed during warfarin interruption in patients who require elective surgery". Thromb Haemost. 2012 Jul 25; 108(2):213-6.
-
Spyropoulos AC, Douketis JD, Gerotziafas G, Kaatz S, Ortel TL, Schulman S. Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. J Thromb Haemost. 2012 Apr; 10(4):692-4.
-
Ageno W, Spyropoulos AC, Turpie AG. Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. Thromb Haemost. 2012 May 31; 107(6):1027-34.
-
Mahan C, Spyropoulos AC. Improving prevention and treatment of venous thromboembolism: clinical trial results. J Med Econ. 2012; 15(4):611-22.
-
Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R. Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; 141(2 Suppl):e326S-50S.
-
Warkentin TE, Pai M, Sheppard JI, Schulman S, Spyropoulos AC, Eikelboom JW. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost. 2011 Dec; 9(12):2389-96.
-
Mahan CE, Hussein MA, Amin AN, Spyropoulos AC. Venous thromboembolism pharmacy intervention management program with an active, multifaceted approach reduces preventable venous thromboembolism and increases appropriate prophylaxis. Clin Appl Thromb Hemost. 2012 Jan; 18(1):45-58.
-
Mahan CE, Holdsworth MT, Welch SM, Borrego M, Spyropoulos AC. Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event. Thromb Haemost. 2011 Sep; 106(3):405-15.
-
Kaatz S, Spyropoulos AC. Venous thromboembolism prophylaxis after hospital discharge: transition to preventive care. Hosp Pract (Minneap). 2011 Aug; 39(3):7-15.
-
Shroff A, Chung HO, Khalidi NA, Spyropoulos A. Antiphospholipid syndrome and the aorta: a rare presentation. J Rheumatol. 2011 Aug; 38(8):1808-9.
-
Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos A, Tapson V. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis. 2011 May; 31(4):407-16.
-
Spyropoulos AC, Anderson FA, Fitzgerald G, Decousus H, Pini M, Chong BH, Zotz RB, Bergmann JF, Tapson V, Froehlich JB, Monreal M, Merli GJ, Pavanello R, Turpie AG, Nakamura M, Piovella F, Kakkar AK, Spencer FA. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011 Sep; 140(3):706-14.
-
Huo MH, Spyropoulos AC. The eighth American college of chest physicians guidelines on venous thromboembolism prevention: implications for hospital prophylaxis strategies. J Thromb Thrombolysis. 2011 Feb; 31(2):196-208.
-
Goldenberg NA, Spyropoulos AC, Halperin JL, Kessler CM, Schulman S, Turpie AG, Skene AM, Cutler NR, Hiatt WR. Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. Blood. 2011 Feb 17; 117(7):2089-92.
-
Spyropoulos AC. Risk assessment of venous thromboembolism in hospitalized medical patients. Curr Opin Pulm Med. 2010 Sep; 16(5):419-25.
-
Spyropoulos AC. Bridging therapy and oral anticoagulation: current and future prospects. Curr Opin Hematol. 2010 Sep; 17(5):444-9.
-
Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK, Merli GJ, Monreal M, Nakamura M, Pavanello R, Pini M, Piovella F, Spencer FA, Spyropoulos AC, Turpie AG, Zotz RB, Fitzgerald G, Anderson FA. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest. 2011 Jan; 139(1):69-79.
-
Amin A, Spyropoulos AC, Dobesh P, Shorr A, Hussein M, Mozaffari E, Benner JS. Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start). J Thromb Thrombolysis. 2010 Apr; 29(3):326-39.
-
Mahan CE, Pini M, Spyropoulos AC. Venous thromboembolism prophylaxis with unfractionated heparin in the hospitalized medical patient: the case for thrice daily over twice daily dosing. Intern Emerg Med. 2010 Aug; 5(4):299-306.
-
Mahan CE, Spyropoulos AC. Venous thromboembolism prevention: a systematic review of methods to improve prophylaxis and decrease events in the hospitalized patient. Hosp Pract (Minneap). 2010 Feb; 38(1):97-108.
-
Spyropoulos AC. To bridge or not to bridge: that is the question. The argument FOR bridging therapy in patients on oral anticoagulants requiring temporary interruption for elective procedures. J Thromb Thrombolysis. 2010 Feb; 29(2):192-8.
-
Douketis JD, Spyropoulos AC. Vitamin K to reverse the anticoagulant effect of vitamin K antagonists: can you teach an old dog new tricks? J Thromb Haemost. 2010 Mar; 8(3):496-8.
-
Spyropoulos AC. Letter by Spyropoulos regarding article, "Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients". Circulation. 2009 Dec 15; 120(24):e288.
-
Spyropoulos AC, Mahan C. Venous thromboembolism prophylaxis in the medical patient: controversies and perspectives. Am J Med. 2009 Dec; 122(12):1077-84.
-
Spyropoulos AC, Hussein M, Lin J, Battleman D. Rates of venous thromboembolism occurrence in medical patients among the insured population. Thromb Haemost. 2009 Nov; 102(5):951-7.
-
Spyropoulos AC, Hussein M, Lin J, Battleman D. Rates of symptomatic venous thromboembolism in US surgical patients: a retrospective administrative database study. J Thromb Thrombolysis. 2009 Nov; 28(4):458-64.
-
Merli G, Spyropoulos AC, Caprini JA. Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations. Ann Surg. 2009 Aug; 250(2):219-28.
-
Gerotziafas GT, Dupont C, Spyropoulos AC, Hatmi M, Samama MM, Kiskinis D, Elalamy I. Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin. Thromb Haemost. 2009 Jul; 102(1):42-8.
-
Spyropoulos AC. Upper vs. lower extremity deep vein thrombosis: outcome definitions of venous thromboembolism for clinical predictor rules or risk factor analyses in hospitalized patients. J Thromb Haemost. 2009 Jun; 7(6):1041-2.
-
Alikhan R, Spyropoulos AC. Epidemiology of venous thromboembolism in cardiorespiratory and infectious disease. Am J Med. 2008 Nov; 121(11):935-42.
-
Spyropoulos AC. Brave new world: the current and future use of novel anticoagulants. Thromb Res. 2008; 123 Suppl 1:S29-35.
-
Spyropoulos AC. Insights from the 7th Southwest Symposium on Thrombosis and Hemostasis. Thromb Res. 2008; 123 Suppl 1:S1.
-
Spyropoulos AC, Douketis JD. Guidelines for antithrombotic therapy: periprocedural management of antithrombotic therapy and use of bridging anticoagulation. Int Angiol. 2008 Aug; 27(4):333-43.
-
Spyropoulos AC, Turpie AG, Dunn AS, Kaatz S, Douketis J, Jacobson A, Petersen H. Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). Am J Cardiol. 2008 Oct 1; 102(7):883-9.
-
Spyropoulos AC, Magnuson S, Koh SK. The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes. Ther Clin Risk Manag. 2008 Jun; 4(3):653-7.
-
Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, Ansell J. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):299S-339S.
-
Deitelzweig SB, McKean SC, Amin AN, Brotman DJ, Jaffer AK, Spyropoulos AC. Prevention of venous thromboembolism in the orthopedic surgery patient. Cleve Clin J Med. 2008 Apr; 75 Suppl 3:S27-36.
-
Haas S, Spyropoulos AC. Primary prevention of venous thromboembolism in long-term care: identifying and managing the risk. Clin Appl Thromb Hemost. 2008 Apr; 14(2):149-58.
-
Jaffer AK, Amin AN, Brotman DJ, Deitelzweig SB, McKean SC, Spyropoulos AC. Prevention of venous thromboembolism in the hospitalized medical patient. Cleve Clin J Med. 2008 Apr; 75 Suppl 3:S7-16.
-
Spyropoulos AC, Brotman DJ, Amin AN, Deitelzweig SB, Jaffer AK, McKean SC. Prevention of venous thromboembolism in the cancer surgery patient. Cleve Clin J Med. 2008 Apr; 75 Suppl 3:S17-26.
-
Garcia DA, Spyropoulos AC. Update in the treatment of venous thromboembolism. Semin Respir Crit Care Med. 2008 Feb; 29(1):40-6.
-
Spyropoulos AC. Outpatient-based primary and secondary thromboprophylaxis with low-molecular-weight heparin. Clin Appl Thromb Hemost. 2008 Jan; 14(1):63-74.
-
Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost. 2007 Nov; 5(11):2211-8.
-
Spyropoulos AC. To bridge or not to bridge, that is the question. Intern Emerg Med. 2007 Jun; 2(2):145-7.
-
Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm. 2007 Jul-Aug; 13(6):475-86.
-
Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, Spyropoulos AC, Merli GJ, Zotz RB, Bergmann JF, Pavanello R, Turpie AG, Nakamura M, Piovella F, Kakkar AK, Spencer FA, Fitzgerald G, Anderson FA. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest. 2007 Sep; 132(3):936-45.
-
Spyropoulos AC. Investigational treatments of venous thromboembolism. Expert Opin Investig Drugs. 2007 Apr; 16(4):431-40.
-
Hyers TM, Spyropoulos AC. Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin. J Thromb Thrombolysis. 2007 Dec; 24(3):225-32.
-
Pini M, Spyropoulos AC. Prevention of venous thromboembolism. Semin Thromb Hemost. 2006 Nov; 32(8):755-66.
-
Spyropoulos AC. Prevention of venous thromboembolism: clinical and economic implications. Introduction. Am J Health Syst Pharm. 2006 Oct 15; 63(20 Suppl 6):S3-4.
-
Spyropoulos AC, Turpie AG, Dunn AS, Spandorfer J, Douketis J, Jacobson A, Frost FJ. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost. 2006 Jun; 4(6):1246-52.
-
Spyropoulos AC, Bauersachs RM, Omran H, Cohen M. Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy. Curr Med Res Opin. 2006 Jun; 22(6):1109-22.
-
Spyropoulos AC. Managing oral anticoagulation requires expert experience and clinical evidence. J Thromb Thrombolysis. 2006 Feb; 21(1):91-4.
-
Spyropoulos AC, Merli G. Management of venous thromboembolism in the elderly. Drugs Aging. 2006; 23(8):651-71.
-
Bullano MF, Willey V, Hauch O, Wygant G, Spyropoulos AC, Hoffman L. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm. 2005 Oct; 11(8):663-73.
-
Tateo S, Mereu L, Salamano S, Klersy C, Barone M, Spyropoulos AC, Piovella F. Ovarian cancer and venous thromboembolic risk. Gynecol Oncol. 2005 Oct; 99(1):119-25.
-
Cohen AT, Alikhan R, Arcelus JI, Bergmann JF, Haas S, Merli GJ, Spyropoulos AC, Tapson VF, Turpie AG. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost. 2005 Oct; 94(4):750-9.
-
Spyropoulos AC, Turpie AG. Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulation. Curr Opin Pulm Med. 2005 Sep; 11(5):373-9.
-
Spyropoulos AC. Bridging of oral anticoagulation therapy for invasive procedures. Curr Hematol Rep. 2005 Sep; 4(5):405-13.
-
Spyropoulos AC. Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients. Chest. 2005 Aug; 128(2):958-69.
-
Spyropoulos AC. Management of venous thromboembolism: why not treat it at home? Can Fam Physician. 2005 Feb; 51:181-2, 184-5.
-
Spyropoulos AC. Perioperative bridging therapy for the at-risk patient on chronic anticoagulation. Dis Mon. 2005 Feb-Mar; 51(2-3):183-93.
-
Spyropoulos AC. Pharmacologic therapy for the management of thrombosis: unfractionated heparin or low-molecular-weight heparin? Clin Cornerstone. 2005; 7(4):39-48.
-
Nutescu EA, Spyropoulos AC, Cranmer KW. Oral anticoagulation: preparing for change. J Am Med Dir Assoc. 2004 Sep-Oct; 5(5 Suppl 1):2-11.
-
Willey VJ, Bullano MF, Hauch O, Reynolds M, Wygant G, Hoffman L, Mayzell G, Spyropoulos AC. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther. 2004 Jul; 26(7):1149-59.
-
Spyropoulos AC, Jenkins P, Bornikova L. A disease management protocol for outpatient perioperative bridge therapy with enoxaparin in patients requiring temporary interruption of long-term oral anticoagulation. Pharmacotherapy. 2004 May; 24(5):649-58.
-
Spyropoulos AC, Frost FJ, Hurley JS, Roberts M. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest. 2004 May; 125(5):1642-50.
-
Spyropoulos AC, Haire W. The clinical thrombosis center and clinical thrombologist: a new US health systems paradigm for the management of venous thromboembolic disease. J Thromb Thrombolysis. 2003 Jun; 15(3):227-32.
-
Talmadge DB, Spyropoulos AC. Purple toes syndrome associated with warfarin therapy in a patient with antiphospholipid syndrome. Pharmacotherapy. 2003 May; 23(5):674-7.
-
Spyropoulos AC, Hayth KA, Jenkins P. Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr; 23(4):533-6.
-
Spyropoulos AC, Hurley JS, Ciesla GN, de Lissovoy G. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. Chest. 2002 Jul; 122(1):108-14.
-
Spyropoulos AC. The use of a protocol for the treatment of deep vein thrombosis. Am J Manag Care. 2001 Nov; 7(17 Suppl):S553-8.
-
Spyropoulos AC. Prevention of bleeding in older patients taking warfarin. Ann Intern Med. 2001 Oct 2; 135(7):548; author reply 549.
-
Spyropoulos AC. Outpatient-based treatment protocols in the management of venous thromboembolic disease. Am J Manag Care. 2000 Nov; 6(20 Suppl):S1034-44.
-
Spyropoulos AC. Reimbursement strategies in an outpatient-based disease management program for the treatment of deep venous thrombosis in an integrated health care system. Manag Care. 1999 Dec; 8 Suppl:14-20.
-
Spyropoulos AC. Membranous obstruction of the inferior vena cava and extensive bone marrow necrosis associated with catastrophic antiphospholipid syndrome. J Clin Rheumatol. 1999 Oct; 5(5):279-84.
-
Spyropoulos AC. Outpatient protocols for treatment of venous thromboembolism using low-molecular-weight heparin: to treat or not to treat at home. Arch Intern Med. 1999 May 24; 159(10):1139-40.
